RxDoctor Payments Data

Christopher Hong, MD

Cardiovascular Disease · North Chelmsford, MANPI 1730234626

Payments from drug & device makers

$33,831in general payments, 2019–2025

Across 54 payments — averaging $626.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$33K
  • E.r. Squibb & Sons, L.L.C.$114
  • Novartis$73
  • Pfizer$71
  • Merck$70
  • AstraZeneca$68
  • plus $300 from 12 others

What the payments were for

  • Consulting fees$33,13598%
  • Food & beverage$6962%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,831 in reported general payments places this provider in the 75th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$256,878
Medicare patients
1,982
Services billed
4,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban425$498,658
XareltoRivaroxaban81$113,467
EntrestoSacubitril/Valsartan42$50,867
Metoprolol Succinate392$8,025
Atorvastatin Calcium432$6,592
Rosuvastatin Calcium133$4,127
Losartan Potassium268$3,319
Labetalol Hcl89$2,320
Diltiazem 24hr Er (Cd)Diltiazem Hcl69$2,027
Amlodipine Besylate276$2,021
Flecainide Acetate24$1,938
Chlorthalidone79$1,820
ClopidogrelClopidogrel Bisulfate104$1,742
Furosemide327$1,648
Lisinopril245$1,582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$71$498,658425 claims
NovartisEntresto$73$50,86742 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in North Chelmsford

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →